Rasagiline, a MAO-B inhibitor preferentially selective for MAO-B over MAO-A approved in many countries to treat Parkinson’s disease, was assessed for its occupancy and persistence of such after cessation of this medication. This evidence concerns the gene MAOB and Parkinson disease.